Tasso Inc.

10 articles about Tasso Inc.

• Tasso Announces Launch of Tasso Care® for Prescreening

  2/8/2024

  Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, announced the launch of Tasso Care® for Prescreening, an end-to-end services solution to maximize the success of a prescreening program.

• Tasso Receives CE Mark Certification for Tasso+™, Latest Generation Whole Blood Collection Lancet Device

  9/19/2023

  Tasso, Inc. today announced it received CE Mark certification for its Tasso+™ device, a convenient, virtually pain-free blood lancet that collects whole liquid blood samples.

• Tasso and UBC Partner to Advance Decentralized Sample Collection and Analysis Solutions for Post-Approval Research

  6/27/2023

  Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, and United BioSource LLC (UBC) today announced a partnership to provide more efficient, streamlined, and convenient sample collection and analysis options for post-approval research to improve study design and enable a better patient experience.

• Tasso Recommended for Certification from Medical Device Single Audit Program (MDSAP)

  5/18/2023

  Tasso, Inc. today announced that it has been recommended for certification from the Medical Device Single Audit Program (MDSAP), under which a single regulatory audit of a medical device manufacturer may satisfy the requirements of multiple regulatory jurisdictions participating in the program.

• Tasso High-Volume Liquid Blood Collection Device Earns CE Mark Certification

  2/14/2023

  Tasso, Inc. today announced that the TassoOne™ Plus, a new high-volume liquid blood collection device, has received CE Mark certification and successfully fulfilled all of the performance, safety, and relevant product requirements under the new European Union Medical Device Regulation.

• 

  FDA Review: Abiomed, Mallinckrodt, Aro and More

  9/16/2022

  The FDA has a broad range of activities in the drug and medical device space. Here’s a look at the agency’s work this week.

• Tasso+™ Device Earns FDA 510(k) Class II Medical Device Clearance

  9/14/2022

  Tasso, Inc., the leading provider of convenient, clinical-grade blood collection solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Tasso+™ lancet as a Class II medical device.

• 

  Money on the Move: December 15 – 21

  12/22/2021

  These biotech companies made the nice list, earning them far more than a lump of coal.

• Tasso Secures $100M in Series B Financing

  12/16/2021

  Tasso, Inc., a leader in clinical-grade blood collection technology, announced that it has completed an oversubscribed $100 million Series B financing round, bringing the total funding to date to $131 million.

• Tasso-M20 Device Earns CE Mark Certification for At-Home, Self-Sampling Blood Collection

  5/19/2021

  Leading European pharmaceutical companies are using the device across multiple virtual clinical trials to gather unprecedented amounts of pharmacokinetic data